Annex A: Project Descriptions

Company: 16 Bit Inc.
Project Name: Rho: AI-driven Opportunistic Screening for Low Bone Density on X-ray
About the Company: 16 Bit is a Canadian medical imaging AI company founded by radiologists. The company's mission is to improve the quality, efficiency, and accessibility of preventive healthcare globally.
About the Solution:
Rho is a Health Canada, US FDA, Australian TGA and Singapore HSA–approved AI software-as-a-medical-device (SaMD) that enables opportunistic osteoporosis screening using routine X-rays. Osteoporosis often remains undiagnosed until fractures occur, yet millions of chest, spine, pelvis, and extremity X-rays are performed each year without bone health assessment.

Rho analyses these existing images to generate a score from 1 to 10, identifying patients at increased risk of low bone mineral density. Patients with a positive Rho result (score ≥ 6) can then be referred for Dual-Energy X-ray Absorptiometry (DXA) scanning, the diagnostic gold standard. This approach unlocks new value from existing imaging workflows, improves early detection rates, and facilitates preventive interventions to reduce fracture risk.

Deployed in radiology, orthopaedic and primary care clinics, Rho supports clinicians in identifying at-risk patients, increases DXA referrals, and strengthens quality of care while generating new revenue opportunities for providers. With approvals across multiple regulatory jurisdictions and expanding partnerships in the Americas, Asia, and Europe, Rho is poised to become the global standard for opportunistic osteoporosis screening.

Company: Acorai AB
Project Name: Acorai Device – Non-invasive Heart Failure Monitor
About the Company: Acorai is a Swedish MedTech company transforming heart failure management through a non-invasive, FDA Breakthrough–designated device for right and left sided cardiac pressure monitoring.
About the Solution:
Acorai has developed a breakthrough solution for heart failure management: a non-invasive device capable of accurately estimating both right atrial and pulmonary capillary wedge pressures. Current gold-standard methods, such as right heart catheterisation, are invasive, resource-intensive, and impractical for routine monitoring. Acorai's device, powered by the patented SAVE Sensor System, combines seismic, acoustic, visual, and electric biosignals analysed through advanced machine learning trained on a proprietary global dataset of more than 2,000 patients.

In clinical validation studies across 20 leading hospitals in the US, Europe, and Canada, Acorai has demonstrated superior accuracy to existing non-invasive tools, meeting and exceeding clinical requirements for pressure assessment. The device records data in just five minutes and provides actionable pressure estimates directly at the bedside or in community care. This enables earlier detection of congestion, more precise therapy personalisation, and optimised discharge decisions.

By spanning the entire patient journey – from emergency triage and inpatient monitoring to long-term community management – Acorai delivers faster, more cost-effective care while reducing costly re-admissions.

With over US$13 million invested, multiple patents granted, and FDA/EU approvals anticipated in 2026, Acorai is uniquely positioned to reshape heart failure therapy and generate significant clinical and economic impact.

Company: AI Medical Service Pte Ltd
Project Name: gastroAI – Eliminating Missed GI Cancer Diagnosis Through Endoscopic AI
About the Company: AI Medical Service (AIM) is a Tokyo-headquartered startup dedicated to eliminating gastrointestinal (GI) cancers through AI-powered endoscopy. By enhancing early detection and reducing diagnostic oversight, AIM empowers clinicians to identify cancers earlier, improving patient outcomes and addressing the global shortage of skilled endoscopists.
About the Solution:
gastroAI is AIM's real-time, AI-powered diagnostic support tool that helps endoscopists detect early-stage gastric cancers during upper GI endoscopy. Designed to reduce missed detections, gastroAI acts as an extra set of expert eyes, enabling earlier and more accurate diagnoses when treatment is most effective.

The system integrates seamlessly into existing clinical workflows. It is plug-and-play, requiring only a single cable connection to standard Olympus or Fujifilm endoscope systems, with no changes to hospital infrastructure. AI-generated confidence scores appear in real time on a second monitor or the main screen whenever the endoscopist captures an image of the inside of the stomach.

gastroAI is HSA-approved in Singapore and built with data privacy and reliability in mind. It operates fully offline and unidirectionally, ensuring no patient data is stored or transmitted and eliminating risks linked to network failures.

Patients benefit from earlier detection, improved survival, reduced anxiety, and lower treatment costs. Endoscopists gain better diagnostic accuracy, less fatigue, and fewer unnecessary biopsies, all without disrupting existing workflows.

AIM is redefining the future of endoscopy with AI. With innovative real-time tool and market-ready product, the company is expanding into colonoscopy and cloud-based solutions, ready to scale globally and bring earlier cancer detection to patients and clinicians worldwide.

Company: Better Medicine OÜ
Project Name: Opportunistic Screening: Incidental Kidney Cancer Findings from CT Scans
About the Company: Better Medicine leverages AI to transform oncology diagnostics, ensuring cancers are detected earlier and monitored more effectively. By combining automated and human-guided lesion management, the solutions enhance radiology workflows, reduce missed findings, and enable faster, more accurate diagnoses, driving better outcomes and improved care for patients worldwide.

About the Solution:
Early detection of kidney cancer can be challenging because symptoms can often be non-specific and easily misattributed to other common conditions. Research shows that over 60% of kidney cancer cases are detected incidentally (Bradley et al., 2021).

BMVision Kidney is the world's first CE-marked and clinically validated AI model for detecting and characterising kidney lesions from contrast-enhanced computed tomography (CT) scans. The solution identifies lesions with malignant and benign features and automatically provides key measurements, including volume, true longest dimension, and three orthogonal dimensions. Fully compliant with Digital Imaging and Communications in Medicine (DICOM) standards, it integrates seamlessly into picture archiving and communication system (PACS), with flexible cloud-based deployment available.

In a study at Tartu University Hospital, Estonia, combining BMVision Kidney with radiologists achieved 99.2% sensitivity when detecting lesions with malignant characteristics, and 95% for lesions with benign characteristics (publication pending).

BMVision Kidney represents a breakthrough in AI-driven oncology imaging, offering clinicians a powerful tool to detect, measure, and monitor kidney cancer with unprecedented accuracy and efficiency.

References: Bradley A.J., Maskell G.F., Mannava A., Pollard A., Welsh T. (2021) Routes to diagnosis and missed opportunities in the detection of renal cancer, Clinical Radiology, 76(2), p129-134.

Company: Gense Technologies Limited
Project Name: Mediscan
About the Company: Gense is a health screening device company backed by Alibaba Entrepreneurs Fund, Gobi Partners, Particle X, HKUST, and Cyberport. The company develops devices and solutions for preventive healthcare and chronic disease management. Gense is also the winner of Jumpstarter 2022, Forbes 100 to Watch, and ICT Startup Awards Grand Award.
About the Solution:
Gense offers Mediscan, a medical imaging device for preventive screening and chronic disease monitoring in lung, liver, and kidney. Applicable for home care and primary care, the device monitors some of the most prevalent chronic diseases including lung function, fatty liver disease, and chronic kidney disease.

Specifically, users can connect the palm-sized IoT device to their tablets, follow simple in-app instructions for 1-minute zero-radiation scans, and receive easy-to-read clinically benchmarked results within minutes via cloud-based AI algorithms. Generated reports allow for actionable insights, such as diet and exercise, for personalised health improvement.

Mediscan can be deployed in clinics, corporate healthcare services, home care services, elderly services, and more. The device is operable by social workers for high-throughput and scalable screening services.

The technology is developed by a team of researchers in Hong Kong and clinically validated at the University of Hong Kong and Queen Mary Hospital. The research has generated 9 patents and has been featured in 19 publications including Nature Scientific Reports. Mediscan is also an accredited medical electrical equipment under IEC60601 with ISO 13485 Medical Device certification.

Company: GyroGear Pte Ltd
Project Name: AI-Driven Adaptive Modulation and Management of Hand Tremors
About the Company: GyroGear is a neurotech company restoring independence to people with hand tremors.
About Solution:
Approximately 200 million individuals globally suffer from lifelong, incurable hand tremors (Parkinson's disease, essential tremor). Today's therapies are inadequate - medication has significant side effects, while neurosurgery remains risky. Wearable options remain extremely limited. GyroGlove 1.0 thus provides instant restoration of quality of life.

Yet patients face minimal long-term care options - treatment options are limited, and tremors are extremely variable and there is limited clinical understanding. Navigating side-effects, such as physiotherapy and mental health in old age can be taxing.

We are thus building GyroCare, the world's first tremor management ecosystem. GyroGlove instantly steadies hands, while embedded sensors quantify tremor patterns. Patients gain real-time feedback and restored independence; clinicians receive objective, longitudinal data to guide treatment.

The integration of patient and clinician access greatly accelerates optimisation of GyroCare's AI and interaction interfaces. Reinforcement learning algorithms adapt to highly variable tremor severities, subtypes and progression, providing timely, clinically meaningful alerts while conserving device energy. Users and families finally have organised, actionable information of a complex, life-long condition. Physicians too have always asked us for continuous monitoring, early warnings, multimodal treatment optimisation, multi-disease capability, etc.

We must make this human-centred care possible for fellow Singaporeans, and the global tremor community.

Company: LIFESCAPES Inc.
Project Name: Brain-Computer Interface for Neurorehabilitation
About the Company: LIFESCAPES, a Keio University–origin startup, develops Brain-Computer Interface (BCI) technology to restore motor function for patients with severe paralysis caused by stroke or spinal cord injury. Our mission is to enable patient recovery, improve quality of life, and support healthcare providers with innovative, clinically validated rehabilitation solutions.
About Solution:
LIFESCAPES' BCI solution enables patients with severe motor impairments, traditionally considered untreatable, to regain hand function. Using electroencephalogram (EEG)

biomarkers, the system monitors brain activity linked to motor intention, allowing real-time detection of movement attempts. This signal is translated into precise interventions via wearable robotics and electrical stimulation, creating an effective rehabilitation loop.

The technology integrates patient-led, autonomous training with clinical workflows. The BCI system automatically adjusts intervention intensity based on the patient's progress, while EEG and AI-derived insights can guide rehabilitation strategies, such as prioritising functional recovery or activities of daily living. This approach reduces dependency on continuous supervision and allows healthcare providers to focus on high-priority tasks.

Clinically validated in over 800 cases in Japan, our solution demonstrates significant motor recovery within two weeks of training, far shorter than competing devices requiring 12-week protocols. Its design supports home and inpatient use, enhancing accessibility, efficiency, and patient engagement. By combining physiological monitoring with adaptive therapy, LIFESCAPES' BCI technology improves patient outcomes, shortens hospitalisation, and offers scalable, evidence-based rehabilitation for global markets.

Company: NalaGenetics Pte Ltd
Project Name: From Trial-and-Error to Precision Medicine: Nala RxMax for Efficient PGx Implementation
About the Company: Nalagenetics develops highly accurate predictive genetic testing for diverse populations at risk of cardiovascular, metabolic, cancer, and neurodegenerative diseases. Unlike current germline sequencing analysing <2% of the genome, we use 100% and integrate monogenic, polygenic, and clinical risk scores, improving accuracy 2–48x for sensitive, comprehensive, and cost-effective results.
About the Solution:
Nala Clinical Decision Support (RxMax) is an end-to-end pharmacogenomics (PGx) platform that embeds genetic insights into everyday prescribing to reduce adverse drug reactions (ADRs) and improve treatment precision. In Singapore, ADRs contribute to 8.1% of hospital admissions and cost the healthcare system over US$168 million annually—many of which are preventable.

RxMax combines four components: an AI-powered chatbot to streamline pre-test consultations, a bioinformatics engine compatible with multiple sequencing technologies, an EHR-integrated clinical decision support (CDS) platform, and a patient-facing mobile app for report access and sharing. To ensure operational readiness, Nala has partnered with a College of American Pathologists (CAP) accredited lab in Singapore for sample processing and is in the process of integrating with the National Electronic Health Record (NEHR) to enable seamless prescribing support.

Validated in clinical pilots with PRECISE (Singapore) and Raffles Medical Group, RxMax has demonstrated high prevalence of actionable PGx variants (95%) and real-world prescription adjustments (21.2%). Regionally, it has supported over 10,000 reports in Indonesia's BGSi population sequencing programme, proving scalability across diverse healthcare systems. With flexible, platform-agnostic deployment, RxMax enables safer, cost-effective prescribing in cardiology, oncology, psychiatry, and beyond—aligning with Singapore's precision medicine

agenda while delivering measurable reductions in ADRs, hospital readmissions, and healthcare costs.

Company: NDR Medical Technology Pte Ltd
Project Name: AI Lung Tumor Detection and Visualisation – NDAnalyzer
About the Company: NDR Medical develops AI image-guided solution to enable safe and accurate interventional access into different anatomy targeting lesions and nodules, enabling early detection and treatment of cancer, as well as superior clinical outcome for surgical procedures.
About the Solution:
NDAnalyzer is a software solution to assist surgeons and interventional radiologists during pre-operative planning and intraoperative procedure. The 3D segmentation and nodule identification feature make it ideal during patient consultation, providing a visual explanation of treatment plans. The software can be integrated to PACS system for seamless receiving of Patient DICOM scans either in real-time or with post scan analysis.

Company: Oncoustics, Inc.
Project Name: OnX Liver Assessment Solution: Advancing Diagnostics for Liver Disease
About the Company: Oncoustics creates advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. By applying AI to raw ultrasound signals, we reveal novel acoustic biomarkers and perform virtual biopsies, thereby avoiding expensive and invasive diagnostics for better triage and early interventions.
About the Solution:
The OnX Liver Assessment Solution is indicated for non-invasive ultrasound acquisition and provides estimates of stiffness as well as measurement of the ultrasound attenuation coefficient. The estimates of stiffness and ultrasound attenuation measurements may be used as an aid in the diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver.

OnX is a clinical decision support tool that is predicated on Fibroscan (transient elastography) and shear wave elastography to enable. Unlike these devices however, the OnX is low cost and pocket sized. As the solution guides the data acquisition, it does not require a trained sonographer to perform the exam. Since the results are quantitative, it does not require a radiologist to interpret the exam.

Annex B: SLINGSHOT 2025

Organised by Enterprise Singapore, Slingshot 2025 will be held at the Singapore Week of Innovation and Technology (SWITCH) 2025 from 29 to 31 October 2025.

One of the CHISEL Healthcare InnoMatch 2025 finalists will be selected and fast-tracked to the Top 60 SLINGSHOT ('fast-tracked CHISEL').



Benefits to selected 'fast-tracked CHISEL':

- Awarded StartupSG Grant Prize worth S$50,000.
- Opportunity to pitch at the Health and Biomedical Domain Finals, where the Top 3 of the Domain will receive additional Startup SG Grant Prize worth S$60,000.
- If selected, to compete in the SLINGSHOT Grand Finals where the Top 3 will receive S$200,000 to S$400,000 and 6 to 18 months of rent-free space at JTC Launchpad.
- Opportunity to participate in activities (eg: mentorship, pitch coaching) planned for Domain Finalists. If the selected startup resides outside of Singapore, one return flight and accommodation (subject to a maximum of 10 days) in Singapore will be sponsored by EnterpriseSG.
- One complimentary SWITCH 2025 exhibition space.